治療用／診断用抗体産業の動向

Abstract

Monoclonal antibody drugs offer several advantages over other types of drugs. Technologically, antibodies exhibit amazing specificity that allows for a safe and targeted attack on disease-causing cells or compounds. The antibody itself may be used as a weapon or the antibody may serve as the vehicle to deliver a drug. Along with high specificity, monoclonal antibodies are effective in a broad range of diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation. Also of great importance is that antibodies are virtually never toxic.

As of May 2005, there were 18 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 500 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 80 of these were in clinical trials.

This BCC report provides detailed market analyses and industry trends. It quantifies and qualifies the emerging market for monoclonal and polyclonal antibody drugs and imaging products. Forecasts and trends are gleaned from industry sources as well as from considered assessments of available and emerging technologies. The study also examines strategies used by biotechnology companies and pharmaceutical firms to develop and market products in this explosive market sector.

Table of Contents

• INTRODUCTION
  • STUDY GOAL AND OBJECTIVES
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • STUDY SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS CREDENTIALS
  • RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
  • BCC ONLINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, THROUGH 2010 ($ MILLIONS)
  • Summary Figure: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, 2002-2010 ($ MILLIONS)
• OVERVIEW
  • DEFINITIONS
    • DEFINITIONS (CONTINUED)
  • THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS
    • THE IMPORTANCE OF・CONTINUED)
  • INTELLECTUAL PROPERTY ISSUES/PATENT LICENSING
  • THE TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
  • Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
  • Table 1 (CONTINUED)
    • ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS
    • WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS AND POLYCLONAL ANTIBODY PRODUCTS DO NOT?
    • VALUATION OF ANTIBODY PRODUCT SALES
• TECHNOLOGY
  • OVERVIEW
    • OVERVIEW (CONTINUED)
    • THE HAMA PROBLEM AND ITS RESOLUTION
    • PHAGE DISPLAY AND POLYSOME DISPLAY
      • Phage Display and Polysome Display (Continued)
    • DIRECTED EVOLUTION
  • ANTIBODY CLASSES
  • ANTIBODY FORMS IN PRODUCTS
    • ABTIDES
    • ANTIBODY CONJUGATES
    • ANTISERUMS
    • BISPECIFIC ANTIBODIES
    • CAMOUFLAGED ANTIBODIES
    • CHIMERIC ANTIBODIES
    • FULLY HUMAN ANTIBODIES
    • HUMANIZED ANTIBODIES
    • PROGENITOR STEM CELLS
    • SINGLE-CHAIN ANTIBODIES
    • SYNTHETIC ANTIBODIES
  • SOURCES OF MONCLONAL ANTIBODIES ON THE MARKET
  • Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES
    • THE SPECIAL CASE OF ENBREL
    • ANTIBODY TECHNOLOGIES IN DEVELOPMENT
      • AFFIBODIES
      • DOMAIN ANTIBODIES
      • NANOBODIES
    • NEW DIRECTIONS IN ANTIBODY RESEARCH
    • THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS
    • THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS
    • THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS
  • Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS)
  • Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS)
    • THE TRANSGENIC ADVANTAGE
    • TRADITIONAL PRODUCTION METHODS
      • MICROBIAL FERMENTATION
      • MAMMALIAN CELL CULTURE
  • Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS
  • Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS
  • Table 6 (CONTINUED)
  • Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES
  • Table 7 (CONTINUED)
    • THE ENBREL SHORTAGE
    • THE CRUNCH IN CAPACITY
    • REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION
    • GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS
    • PRODUCTION OF ANTIBODIES IN ANIMALS
      • PRODUCTION OF ANTIBODIES・CONTINUED)
      • GOATS AS MONOCLONAL ANTIBODIES FACTORIES
      • CHICKENS AS MONOCLONAL ANTIBODIES FACTORIES
    • PRODUCTION OF ANTIBODIES IN PLANTS
      • PLASTIDS
      • TARGETING AND COMPARTMENTALIZING
      • TRANSGENIC SEEDS FOR ANTIBODY STORAGE
    • THE MARKET FOR TRANSGENICALLY PRODUCED ANTIBODY PRODUCTS
  • Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
  • Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
    • PLANTIBODIES IN DEVELOPMENT
  • Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE
  • Table 9 (CONTINUED)
    • ANTI-RABIES ANTIBODIES
    • CARORX
      • Carorx (Continued)
    • CLOSTRIDIUM DIFFICILE TOXIN A AND TOXIN B
    • OTHER THERAPEUTIC PLANTIBODIES IN DEVELOPMENT
    • TECHNOLOGY ISSUES WITH PLANT-BASED HUMAN ANTIBODIES
    • USING MONOCLONAL ANTIBODIES AS CARRIERS FOR CYTOTOXIC DRUGS
    • CONTRACT MANUFACTURING MARKET FOR BIOPHARMACEUTICALS GROWING
  • Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS)
    • CONTRACT MANUFACTURING MARKET・CONTINUED)
    • CONTRACT MANUFACTURING MARKET・CONTINUED)
• PRODUCTS
  • THE MARKET FOR POLYCLONAL AND MONOCLONAL ANTIBODY DRUGS
  • Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS)
  • Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS)
    • THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS
      • THE MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
  • Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
    • Sales by Technology
  • Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
  • Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS)
    • Sales by Target
  • Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
    • THE U.S. MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
  • Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS)
    • Marketed Products
  • Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET
  • Table 16 (CONTINUED)
    • THE EUROPEAN MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
  • Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS)
    • Marketed Products
  • Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET
    • Avastin
      • Avastin (Continued)
      • The Avastin Advantage
      • New Medicare Reimbursement Law Supports Use of Avastin
    • Bexxar
      • Bexxar (Continued)
    • Campath/MabCampath
    • Erbitux
  • Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
  • Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
    • Erbitux (Continued)
    • Herceptin
    • Humira
    • Mylotarg
    • Orthoclone OKT3
    • Panorex
    • Raptiva
    • Remicade
      • Remicade (Continued)
    • ReoPro
      • Reopro (Continued)
      • Reopro (Continued)
    • Rituxan/MabThera
      • Rituxan/Mabthera (Continued)
    • Simulect
    • Synagis
    • Tysabri (formerly Antegren)
    • Xolair
    • Zenapax
    • Zevalin
      • First Radioimmunotherapeutic Drug
      • Results of Trials
      • Sales of Zevalin
    • THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT
  • Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
      • ABT-874
      • AMG 108
      • AMG 162
        • AMG 714
      • Anti-CD20 Humanized Anticlonal Antibody
      • Anti-Tac(Fv)-PE38 Immunotoxin
      • Anti-TGF Beta
      • Avastin
      • CAL
      • Campath
      • Cantuzumab Mertansine
      • CAT-192
      • Cimzia (formerly CDP-870)
      • Cotara
      • Eculizumab
      • Erbitux
      • Felvizumab
      • Herceptin
      • HuMax-CD4
      • HuMax-CD20
      • HuMax-EGFr
      • HuMax-Inflam
      • Humira
      • HuN901-DM1
      • HuZAF
      • IMMU-102 and IMMU-103
      • Lucentis
      • LymphoStat-B
      • M200
      • MDX-010
      • MDX-018
      • MDX-060
      • MDX-070
      • Mepolizumab
      • MLN 02
      • MLN 1202
      • MLN 2704
      • Numax
      • Nuvion
      • Omnitarg
      • Osidem
      • OvaRex
      • Panitumumab
      • Pemtumomab
      • Pexelizumab
      • Pro70769
      • R1569
      • Remicade
      • Rituxan/MabThera
      • SGN-15
      • SGN-30
      • Synagis
      • TheraCIM hR3
      • Trabio
      • Tysabri
      • Vitaxin
      • Xolair
      • Zenapax
    • THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS
      • IMMUNOGLOBULINS
        • Intramuscular Products
        • Intravenous Products
      • NEW APPROACHES TO THE PRODUCTION OF HUMAN POLYCLONAL ANTIBODIES
      • THE MARKET FOR THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS
  • Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
    • MARKETED PRODUCTS
      • ATG-Fresenius S
      • BabyBIG
      • CytoGam
      • Flebogamma
      • Gamimune
      • Gamunex
      • Nabi-HB
      • Octagam
      • Rabies Immune Globulin
      • RespiGam
      • Tetanus Immune Globulin
      • Vaccinia Immune Globulin
      • Varicella-Zoster Immune Globulin
      • WinRho SDF Rho(D) Immune Globulin
      • Anti-Thymocyte Globulin
        • Atgam
        • Thymoglobulin
      • Antitoxins and Antivenins
        • CroFab
        • DigiFab
        • Diphtheria Antitoxin
        • ViperTAb
    • PRODUCTS IN DEVELOPMENT
  • Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  • Table 23 (CONTINUED)
    • Altastaph
    • ATG-Fresenius S
    • CytoFab
    • Nabi-HB Intravenous
    • Thymoglobulin
    • WinRho SDF
    • Early-Stage Products in Development
    • IN VIVO DIAGNOSTIC ANTIBODY PRODUCTS
  • Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
  • Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS)
    • MARKETED PRODUCTS
      • CEA-Scan
      • Humaspect
      • LeukoScan
      • MIBG
      • MyoScint
      • NeutroSpec
      • OctreoScan
      • ProstaScint
      • Verluma
    • PRODUCTS IN DEVELOPMENT
  • Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  • Table 25 (CONTINUED)
    • AFP-Scan
    • Blood Tumor Antibody Diagnostics
      • Blood Tumor Antibody Diagnostics (Continued)
    • CEA-Scan
    • LeukoScan
    • LymphoScan
    • NeutroSpec
    • ProstaScint
    • Tru-Scint AD
    • Tru-Scint AG
• APPLICATIONS
  • LEADING THERAPEUTIC INDICATIONS OF APPROVED MONOCLONAL THERAPEUTIC ANTIBODY PRODUCTS
  • Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
  • Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%)
    • AUTOIMMUNE DISEASES
      • Crohns Disease
      • Psoriasis
      • Rheumatoid Arthritis
      • Antibody Products on the Market for the Treatment of Autoimmune Diseases
  • Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    • Antibodies in Development for the Treatment of Autoimmune Diseases
  • Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  • Table 28 (CONTINUED)
  • Table 28 (CONTINUED)
    • CANCER
      • U.S. Cancer Statistics
  • Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED)
  • Table 30 CANCER PREVALENCE RATES: U.S., 2000
  • Table 30 (CONTINUED)
    • Breast Cancer
    • Colorectal Cancer
    • Head and Neck Cancer
    • Kidney Cancer
    • Leukemias
      • Leukemias (Continued)
    • Liver Cancer
    • Lung Cancer
    • Malignant Melanoma
    • NonHodgkins Lymphoma
    • Osteosarcoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Antibody Products on the Market for the Treatment of Cancer
  • Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
    • Antibodies in Development for the Treatment of Cancer
  • Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS
  • Table 32 (CONTINUED)
  • Table 32 (CONTINUED)
  • Table 32 (CONTINUED)
    • CARDIOVASCULAR DISEASES
  • Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002
  • Table 33 (CONTINUED)
    • Percutaneous Transluminal Coronary Angioplasty
    • Antibody Products on the Market for the Treatment of Cardiovascular Disease
    • Antibodies in Development for the Treatment of Cardiovascular Diseases
  • Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    • INFECTIOUS DISEASES
      • Infectious Diseases (Continued)
      • Cytomegalovirus Infection
      • Hepatitis
      • Respiratory Syncytial Virus Infection
      • Antibodies on the Market for the Treatment of Infectious Diseases
      • Antibodies in Development for the Treatment of Infectious Diseases
  • Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES
  • Table 35 (CONTINUED)
    • OPHTHALMIC DISEASES
      • Macular Degeneration
    • ORGAN TRANSPLANT REJECTION AND GRAFT-VERSUS-HOST DISEASE
      • Organ Transplant Market Size
  • Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004
    • Antibody Products on the Market for the Treatment of Organ Transplant Rejection
  • Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION
    • Antibodies in Development for Organ Transplant Rejection
  • Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION
    • Bone Marrow and Stem Cell Transplantation/Graft-Versus-Host Disease
  • Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004
    • RESPIRATORY DISEASES
      • Allergic Rhinitis and Asthma
      • Allergic Rhinitis and Asthma (Continued)
        • Antibody Products on the Market for the Treatment of Allergic Rhinitis and Asthma
        • Antibodies in Development for the Treatment of Allergic Rhinitis and Asthma
  • Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA
    • OTHER THERAPEUTIC APPLICATIONS
  • Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES
    • DIAGNOSTIC IMAGING APPLICATIONS
      • IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN DEVELOPMENT FOR SELECTED INDICATIONS
  • Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS
• INDUSTRY STRUCTURE
  • ORIGINATORS
  • COMMERCIAL DEVELOPERS
  • VENDORS
  • MANUFACTURERS
  • TECHNOLOGY INNOVATORS
  • PRICING FORECASTS
  • PARTNERSHIPS ABOUND
  • Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004
  • Table 43 (CONTINUED)
    • THE REGULATORY ENVIRONMENT
      • THE REGULATORY ENVIRONMENT (CONTINUED)
    • MARKET SHARE OF MONOCLONAL ANTIBODY PRODUCT MANUFACTURERS
  • Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%)
  • Figure 6 (CONTINUED)
    • GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS
      • GENOMICS AND MONOCLONAL・CONTINUED)
      • GENOMICS AND MONOCLONAL・CONTINUED)
• COMPANY PROFILES
  • ABGENIX, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
      • XenoMouse and XenoMax Technologies
        • Xenomouse And Xenomax・Continued)
      • Technology Advantages
        • Technology Advantages (Continued)
    • CORPORATE STRATEGY
  • AMGEN, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
  • Table 44 AMGENS MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • BIOGEN IDEC, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
        • Corporate Strategy (continued)
    • CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
      • BUSINESS OVERVIEW
      • PRODUCTS
      • CORPORATE STRATEGY
    • CORIXA CORP.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • CYTOGEN CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • GENENTECH, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
  • Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
  • Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
    • GENMAB A/S
      • BUSINESS OVERVIEW
      • PRODUCTS
      • CORPORATE STRATEGY
    • GENZYME CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 47 GENZYMES MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • GTC BIOTHERAPEUTICS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS AND TECHNOLOGIES
        • Products and Technologies (Continued)
        • Monoclonal Antibodies (MAB) and Immunoglobulin (Ig) Fusion Proteins
      • CORPORATE STRATEGY
        • Corporate Strategy (Continued)
        • Corporate Strategy (Continued)
    • IMMUNOMEDICS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 48 IMMUNOMEDICS PRODUCT PIPELINE
  • Table 48 (CONTINUED)
    • CORPORATE STRATEGY
    • MEDAREX, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 49 MEDAREXS PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • MEDIMMUNE, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • LEADING PRODUCTS
  • Table 50 MEDIMMUNES MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • MILLENNIUM PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 51 MILLENNIUMS MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • NABI BIOPHARMACEUTICALS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 52 NABI BIOPHARMACEUTICALS PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • PLANET BIOTECHNOLOGY, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS AND TECHNOLOGY
        • Products and Technology (Continued)
        • CaroRx
        • RhinoRx
        • DoxoRx
    • PROTEIN DESIGN LABS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 53 PROTEIN DESIGN LABS MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • PROTHERICS PLC
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • SYMPHOGEN A/S
      • BUSINESS OVERVIEW
      • PRODUCTS
  • Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES
    • CORPORATE STRATEGY
    • TRANXENOGEN, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS AND TECHNOLOGY
      • CORPORATE STRATEGY
    • VIREXX MEDICAL CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • XOMA LTD.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • YM BIOSCIENCES INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 55 YM BIOSCIENCES PRODUCT PIPELINE
    • CORPORATE STRATEGY
•  
• LIST OF TABLES
• Summary Table:
• Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
• Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES
• Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS)
• Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS)
• Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS
• Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS
• Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES
• Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
• Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE
• Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS)
• Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS)
• Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
• Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
• Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS)
• Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET
• Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS)
• Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET
• Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
• Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
• Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
• Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
• Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
• Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
• Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES
• Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED)
• Table 30 CANCER PREVALENCE RATES: U.S., 2000
• Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
• Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS
• Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002
• Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
• Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES
• Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004
• Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION
• Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION
• Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004
• Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA
• Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES
• Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS
• Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004
• Table 44 AMGENS MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
• Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
• Table 47 GENZYMES MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 48 IMMUNOMEDICS PRODUCT PIPELINE
• Table 49 MEDAREXS PRODUCT PIPELINE
• Table 50 MEDIMMUNES MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 51 MILLENNIUMS MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 52 NABI BIOPHARMACEUTICALS PRODUCT PIPELINE
• Table 53 PROTEIN DESIGN LABS MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES
• Table 55 YM BIOSCIENCES PRODUCT PIPELINE
• LIST OF FIGURES
• Summary Figure:
• Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
• Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS)
• Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS)
• Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS)
• Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%)
• Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%)